Discovering bold new medicines that treat diseases in ways never before possible

ABOUT ARO

Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases.

CENTYRIN PLATFORM

Centyrins are designed to achieve new therapeutic mechanisms by simultaneously targeting multiple cell surface receptors and delivering complex drug payloads to specific cell types and tissues.

 

LATEST NEWS

October 13, 2020

Aro Biotherapeutics Appoints Biotechnology Executive Dr. Christopher Mirabelli to its Board of Directors and Nucleic Acid Therapeutics Expert Dr. Masad Damha to its Scientific Advisory Board

Aro Biotherapeutics

CIC Philadelphia

3675 Market Street, Suite 200

Philadelphia, PA 19104

Email: info@arobiotx.com 

Aro LinkedIn

© 2020 Aro Biotherapeutics Company. All Rights Reserved.